Loading
A phase 2 trial of Osimertinib, Savolitinib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC is a phase 2 interventional study registered as NCT04606771 by AstraZeneca, with 30 participants enrolled, started 2020-09-28 and due to reach its primary completion in 2022-12-21. Interventions recorded: Osimertinib + Savolitinib, Savolitinib + Placebo. Conditions listed: Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2024; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
30 enrolled.
95% CI 28.86 to 82.34; Figures from the ClinicalTrials.gov results section (first posted 2024-09-24), not from a publication · 95% CI 1.55 to 38.35
SourceNA - Not calculated, estimates cannot be calculated due to too few events; Figures from the ClinicalTrials.gov results section (first posted 2024-09-24), not from a publication · 95% CI 7.82 to NA
Source95% CI 5.55 to NA; Figures from the ClinicalTrials.gov results section (first posted 2024-09-24), not from a publication · 95% CI 1.28 to 4.07
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR)primary | Savolitinib Plus Osimertinib | 14 | 57.1% | - | - | link |
| Savolitinib Plus Placebo | 16 | 12.5% | ||||
| Overall Survival (OS) | Savolitinib Plus Osimertinib | 14 | NA - Not calculated, estimates cannot be calculated due to too few events; Figures from the ClinicalTrials.gov results section (first posted 2024-09-24), not from a publication | - | - | link |
| Savolitinib Plus Placebo | 16 | 13.37 months | ||||
| Progression-free Survival (PFS) | Savolitinib Plus Osimertinib | 14 | 7.36 months | - | - | link |
| Savolitinib Plus Placebo | 16 | 1.64 months |
Shares Savolitinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Savolitinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Osimertinib, AstraZeneca.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors.